MORGAN STANLEY: Here are 16 stocks that should thrive no matter what

Regis Duvignau/Reuters

Putting your money in the stock market can be risky, but some stocks are going to thrive no matter what happens to the economy. The trick, then, is finding those stocks.

Morgan Stanley might be able to help.

On Tuesday, Morgan Stanley released its list of "vintage values" stocks for 2017 — 16 stocks that researchers expect to do well over the next year.

To compile this list, the researchers focused on stocks that were rated "overweight" by analysts and also had a favorable risk/reward profile.

"Put simply, we believe these 16 ideas represent our highest-conviction stock ideas for outperformance over the next 12 months," the report states. "Each of these stocks is an attractive one-year buy-and-hold investment opportunity."

We've summarized Morgan Stanley's list here, including projected earnings per share, or EPS, in 2017 and the projected 2017 price-to-earnings, or P/E, ratio, as well as a comment from Morgan Stanley about the stock. Growth stocks with lower P/E-to-growth ratios are generally considered cheaper.

Amgen

Ticker: AMGN

Projected 2017 EPS: $12.98

Projected 2017 P/E: 12

Comment: "We are OW Amgen as we believe the upside from AMGN's pipeline and key near-term data readouts (particularly from the PCSK9 inhibitor outcomes studies) help reduce the long-term risk the company's current base business faces from biosimilars."

Bristol-Myers Squibb

Ticker: BMY

Projected 2017 EPS: $3.37

Projected 2017 P/E: 21.9

Comment: "We rate BMY shares Overweight on very strong growth prospects from a low 2015 earnings base (5-yr EPS CAGR of 25%) ... Consensus appears to underappreciate the margin expansion potential of Bristol."

Charter Communications

Ticker: CHTR

Projected 2017 EPS: $2.98

Projected 2017 P/E: NM

Comment: "Following its acquisition of Time Warner Cable/Bright House, we expect Charter to successfully implement the strategy it has proven out over the last four years on this now larger footprint, driving meaningful OpFCF growth."